March 11th 2025
In patients with low-grade intermediate-risk non-muscle invasive bladder cancer who achieved a CR at 3 months with UGN-102, the 18-month DOR was 80.6%.
February 15th 2025
February 15th 2025
Matthew D. Galsky, MD, on Key Takeaways From 2021 ASCO Annual Meeting in Bladder Cancer
June 9th 2021CancerNetwork® sat down with Matthew D. Galsky, MD, at the 2021 ASCO Annual Meeting to discuss his thoughts on research he believes has the greatest potential to impact standard of care treatment of bladder cancer.
Blue Light Cystoscopy May Help to Identify Bladder Cancer Recurrence Post-BCG
December 4th 2020“Providers should consider using BLC for surveillance of high-risk NMIBC patients undergoing BCG as it could change clinical management by identifying patients who are BCG unresponsive and eligible for alternative therapy and clinical trials,” said Meera Chappidi, MD.
Tremelimumab, Durvalumab Combo Shows Promise for Certain Patients with Localized Bladder Cancer
October 25th 2020Combination treatment with tremelimumab and durvalumab was found to be well-tolerated and showed early signs of activity in certain patients with localized bladder cancer who are not eligible for cisplatin-based chemotherapy.
UroCAD Outperforms Urine Cytology in Detecting Urothelial Carcinoma
October 9th 2020This study suggested that the customized bioinformatics workflow, UroCAD, be used as a noninvasive approach for diagnosis and recurrence surveillance in patients with urothelial carcinoma prior to the use of cystoscopy.
Phase 3 CheckMate-274 Meets Primary End Points in Urothelial Carcinoma
September 25th 2020Researchers suggested these results from CheckMate-274 “point to the potential for nivolumab to become a new standard of care in the adjuvant setting, extending disease-free survival for post-surgery patients with muscle-invasive urothelial cancer without the use of chemotherapy.”
Phase 3 EV-301 Trial of Enfortumab Vedotin-ejfv Meets Primary End Point for Urothelial Cancer
September 18th 2020The clinical trial is comparing enfortumab vedotin-ejfv to chemotherapy in adult patients with locally advanced or metastatic urothelial cancer who were previously treated with a platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor.
Proton Pump Inhibitor Use May Impact Response to Atezolizumab in Patients with Bladder Cancer
September 15th 2020In this study, patients with advanced urothelial carcinoma saw worse outcomes with proton pump inhibitor (PPI) use when treated with atezolizumab, compared with those who were not treated with PPIs.